NCT04473664View on ClinicalTrials.gov

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

July 22, 2021

Study Completion Date

July 22, 2021

Conditions
Hepatic ImpairmentModerate Impaired Hepatic Function
Interventions
DRUG

Quizartinib

Single oral dose, 30 mg tablet

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33147

Advanced Pharma, Miami

33014-3616

Clinical Pharmacology of Miami, LLC, Miami

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT04473664 - A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment | Biotech Hunter | Biotech Hunter